Literature DB >> 24361136

Bosentan, a mixed endothelin receptor antagonist, induces antidepressant-like activity in mice.

Felipe A Pinho-Ribeiro1, Sergio M Borghi1, Larissa Staurengo-Ferrari1, Guilherme B Filgueiras2, Célio Estanislau2, Waldiceu A Verri3.   

Abstract

Endothelins are peptides described initially as potent vasoactive mediators. Recently, studies reported that endothelins can modulate the production and release of cytokines by immune cells. In turn, cytokines are involved in depression disorders and also in the effectiveness of some antidepressants. Therefore, we investigated the effects of treating mice with bosentan, a mixed endothelin receptor antagonist, in widely used models for assessing antidepressant activity of compounds, the forced swimming (FST) and the tail suspension tests (TST). Moreover, the influence of bosentan treatment on circulating IL-6 levels was also addressed after FST. The results show that bosentan treatment induced a bell shaped dose-dependent antidepressant-like effect with increase in circulating IL-6 levels in animals exposed to FST. Bosentan also presented antidepressant-like effect in TST. Similar results were obtained with nortriptyline treatment in the FST and TST. Possible anxiogenic effect of bosentan was excluded using the elevated plus maze test. Therefore, this is the first study to demonstrate the antidepressant-like activity of bosentan in mice, unveiling a previous unrecognized role of endothelin in depression and its possible relation with increased circulating IL-6 levels.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bosentan; Cytokine; Depression; Endothelin

Mesh:

Substances:

Year:  2013        PMID: 24361136     DOI: 10.1016/j.neulet.2013.12.018

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension.

Authors:  Elham Ghasemian; Parisa Motaghian; Alireza Vatanara
Journal:  Adv Pharm Bull       Date:  2016-06-30

2.  Bosentan, a mixed endothelin receptor antagonist, inhibits superoxide anion-induced pain and inflammation in mice.

Authors:  Karla G G Serafim; Suelen A Navarro; Ana C Zarpelon; Felipe A Pinho-Ribeiro; Victor Fattori; Thiago M Cunha; Jose C Alves-Filho; Fernando Q Cunha; Rubia Casagrande; Waldiceu A Verri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-06       Impact factor: 3.000

3.  Induction of distinct neuroinflammatory markers and gut dysbiosis by differential pyridostigmine bromide dosing in a chronic mouse model of GWI showing persistent exercise fatigue and cognitive impairment.

Authors:  Elena V Kozlova; Bruno Carabelli; Anthony E Bishay; Rui Liu; Maximillian E Denys; John C Macbeth; Varadh Piamthai; Meli'sa S Crawford; Declan F McCole; Nicole I Zur Nieden; Ansel Hsiao; Margarita C Curras-Collazo
Journal:  Life Sci       Date:  2021-11-18       Impact factor: 6.780

4.  Multiregional profiling of the brain transmembrane proteome uncovers novel regulators of depression.

Authors:  Shanshan Li; Huoqing Luo; Ronghui Lou; Cuiping Tian; Chen Miao; Lisha Xia; Chen Pan; Xiaoxiao Duan; Ting Dang; Hui Li; Chengyu Fan; Pan Tang; Zhuangzhuang Zhang; Yan Liu; Yunxia Li; Fei Xu; Yaoyang Zhang; Guisheng Zhong; Ji Hu; Wenqing Shui
Journal:  Sci Adv       Date:  2021-07-21       Impact factor: 14.136

5.  Elevated Plasma C-Terminal Endothelin-1 Precursor Fragment Concentrations Are Associated with Less Anxiety in Patients with Cardiovascular Risk Factors. Results from the Observational DIAST-CHF Study.

Authors:  Thomas Meyer; Mira-Lynn Chavanon; Christoph Herrrmann-Lingen; Maren Roggenthien; Kathleen Nolte; Burkert Pieske; Rolf Wachter; Frank Edelmann
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.